Browse Articles
Discover research articles across all indexed journals
In-field progression following radiation therapy as a prognostic biomarker for lutetium-177-PSMA-617 response in metastatic castration-resistant prostate cancer.
86 Background: Prostate cancer often expresses prostate-specific membrane antigen (PSMA), which serves as a diagnostic and therapeutic target. Lutetium-177 ( 177 Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing sites. The prognostic implications of in-field progression (IFP) following prior radiation treatment (RT) on 177 Lu-PSMA-617 response in metastatic castration-resistant prostate cancer (mCRPC) are unknown. Methods: We retrospectively reviewed our experience with 177 Lu-PSMA-617 in mCRPC delivered at multiple community-based practices in the Mountain West. Exclusion criteria included death unrelated to prostate cancer before cycle 3 of 177 Lu-PSMA-617 and completing < 4 cycles by June 1 st , 2024. Baseline characteristics and treatment history were collected. Baseline PSMA PET/CTs were evaluated for maximum SUV, visceral metastases, and lesional heterogeneity (LH) and correlated with radiation records to determine IFP. Progression-free survival (PFS) and overall survival (OS) were determined using Kaplan-Meier and Logrank analysis, and Cox proportional hazard model was used for univariate (UV) and multivariate (MV) analysis of suspected risk factors. Results: In total, 72 patients were evaluated with a median follow-up of 10.9 months. Median PFS was 6.5 months (95%CI [4.4 – 9.3]), and median OS was 15.0 months (95%CI [10.9 – undefined]). Fifty-nine patients received either palliative or definitive RT courses for prostate cancer prior to receiving 177 Lu-PSMA-617. Of the 59 patients, 25 patients demonstrated IFP, 34 did not. In-field progression (UV: HR 2.5, p=.003; MV: HR 2.7, p=.003) and LH (UV: HR 1.9, p=.025; MV: 2.1, p=.036) were found to be risk factors for progression during 177 Lu-PSMA-617 therapy. Median PFS among patients with IFP was 3.9 mo (95%CI [2.6 – 6.3]) versus 10.3 mo (95%CI [4.4 – 13.0]) among those without (p=.002). Median PFS among patients with LH was 4.6 mo (95%CI [2.9 – 6.5]) versus 11.6 mo (95%CI [6.9 – 13.0]) for those without (p=.023). IFP (UV: HR 2.5, p=.016; MV: 2.7, p=.021; median OS = 10.2 mo, 95%CI [6.2 – 12.8]) and LH (UV: HR 2.45, p=.027; MV: HR 4.17, p=.018; median OS = 11.7 mo, 95%CI [9.3 – 15.0]) were similarly prognostic for OS. At the current follow-up, median OS has not been reached for patients without IFP or LH, but Logrank testing shows statistically significant improvements in OS for these groups (p=.013 and p=.022, respectively) over those with them. Conclusions: In our real-world experience, PFS and OS for 177 Lu-PSMA-617 in mCRPC were similar to the VISION study results. IFP following RT and LH on baseline PSMA PET/CT were negative prognostic biomarkers. Validation in a larger, prospective cohort is warranted.
Breakage fusion bridge cycles drive high oncogene number with moderate intratumoural heterogeneity
Abstract Oncogene amplification is a key driver of cancer pathogenesis. Both breakage fusion bridge (BFB) cycles and extrachromosomal DNA (ecDNA) can lead to high oncogene copy numbers, but the impact of BFB amplifications on intratumoral heterogeneity, treatment response, and patient survival remains poorly understood due to detection challenges with DNA sequencing. We introduce an algorithm, OM2BFB, designed to detect and reconstruct BFB amplifications using optical genome mapping (OGM). OM2BFB demonstrates high precision (>93%) and recall (92%) in identifying BFB amplifications across cancer cell lines, patient-derived xenograft models, and primary tumors. Comparisons using OGM reveal that BFB detection with our AmpliconSuite toolkit for short-read sequencing also achieves high precision, though with reduced sensitivity. We identify 371 BFB events through whole genome sequencing of 2557 primary tumors and cancer cell lines. BFB amplifications are prevalent in cervical, head and neck, lung, and esophageal cancers, but rare in brain cancers. Genes amplified through BFB exhibit lower expression variance, with limited potential for regulatory adaptation compared to ecDNA-amplified genes. Tumors with BFB amplifications (BFB(+)) show reduced structural heterogeneity in amplicons and delayed resistance onset relative to ecDNA(+) tumors. These findings highlight ecDNA and BFB amplifications as distinct oncogene amplification mechanisms with differing biological characteristics, suggesting distinct avenues for therapeutic intervention.
Olanzapine for managing side effects from tyrosine-kinase inhibitors.
524 Background: Antiangiogenic tyrosine kinase inhibitors (TKIs) play a key role in treating renal cell carcinoma and other solid organ malignancies, but TKIs cause bothersome side effects that frequently necessitate dose reductions or treatment holds. Olanzapine has been useful for palliating symptoms from classical chemotherapies and advanced cancer, but its effect on TKI-related symptoms is largely unknown. This retrospective study aimed to estimate the efficacy of olanzapine for TKI-induced nausea, vomiting, anorexia, weight loss, and insomnia. Methods: All patients prescribed olanzapine with lenvatinib, cabozantinib, axitinib, or tivozanib at Mayo Clinic between January 1, 2018, and June 30, 2024 were assessed for inclusion. For baseline symptom assessment, clinical care team notes documenting the presence or absence of symptoms and indication(s) for starting olanzapine were reviewed. For response assessment, clinical notes and patient portal messages from the first three months after starting olanzapine were evaluated for qualitative descriptions of change in symptom burden. Relevant data were extracted as direct quotations, which were reviewed by the research team and categorized as “improved,” “worsened,” “stable,” or “missing data.” Each symptom domain was analyzed independently when olanzapine was prescribed for multiple interrelated symptoms. Results: A total of 60 patients who received olanzapine for the treatment of TKI-related adverse effects were included. The most common documented indication for olanzapine was nausea without vomiting (n=35), followed by anorexia (n=25), nausea with vomiting (n=16), weight loss (n=16), and insomnia (n=11). In 32 cases (53%), olanzapine was prescribed for multiple, simultaneous symptoms. Response rates for each symptom domain are shown in the table. In addition, prior to olanzapine, 34 patients (57%) had documented weight loss. Following olanzapine, 50% (n=17) gained weight (median increase: 6.1 kg; range: 2.0 - 10.7 kg), 26% (n=9) stabilized their weight (±1 kg), and 24% (n=8) continued to lose weight. Clinicians utilized a TKI dose reduction within one week of olanzapine initiation in 5 cases (8.3%), and 3 of these patients could resume the higher dose of TKI after starting olanzapine. Only 4 patients (7%) discontinued olanzapine within 3 months due to perceived side effects. Conclusions: Olanzapine appears to be effective in treating TKI-induced nausea, vomiting, anorexia, insomnia, and weight loss. Prospective randomized placebo-controlled studies are needed to confirm these findings. Improvedn (%) Worsened n (%) Stablen (%) Missing Datan (%) Nausea without emesis 32 (84) 3 (8) 1 (3) 2 (5) Nausea with emesis 13 (93) 0 (0) 0 (0) 1 (7) Anorexia 26 (74) 2 (6) 4 (11) 3 (9) Insomnia 11 (85) 0 (0) 2 (15) 0 (0)
Impact of variant allele frequency (VAF) of <i>TP53</i> alterations and Signatera circulating tumor DNA (ctDNA) monitoring for patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV).
830 Background: EV is now a standard of care for pts with aUC, both as monotherapy and with pembrolizumab (EVP). Factors predictive of primary refractory disease (PRD) remain poorly understood. Prior investigation correlated low VAF pathogenic TP53 alterations on next-generation sequencing (NGS) with rapid progression on frontline (1L) platinum chemotherapy. Thus, we hypothesized that low TP53 alteration VAF would associate with inferior outcomes on EV. Methods: We generated an IRB-approved, HIPAA-compliant single institution retrospective database of pts with aUC who received EV monotherapy or in combination, starting 1/2019. Data cutoff was 9/2024. Baseline demographics, clinicopathologic features, and somatic NGS data were extracted from the electronic health record. PRD was defined as progressive disease (PD) on the first restaging scan after starting EV or earlier clinical progression resulting in death from disease. Signatera ctDNA was collected every 1-3 months. Statistical analysis included Fisher’s exact test. Results: We identified 82 pts with aUC who received EV, of whom 35 had available NGS data on tumor tissue. 22 pts (63%) had a TP53 alteration with reported VAF, with a median of 48.7% (range 12.1%-81.9%). Amongst the 35 pt cohort, at EV start, median age was 69 yrs, 65% male, 83% white, 40% never smokers, 23% with variant predominant histology, 17% upper tract disease, and metastatic sites included lymph node (77%), lung (26%), liver (20%), and bone (9%). 21 pts received EV as 1L therapy, and 14 pts received EV in the refractory setting (2L+). 21 pts received EVP, 1 pt received EVP with carboplatin, and 13 pts received EV monotherapy. Median follow-up time from EV start was 6.5 months, and 54% of pts were alive at data cutoff. For 1L EV, 29% (6/21) had PRD. Observed response rate (ORR) was 81% (13/16) at first restaging scan. For 2L+ EV, PRD rate was 43% (6/14), and ORR at first restaging scan was 55% (6/11). 8 of 22 pts (36%) with TP53 alteration had PRD. Pts with TP53 VAF below the median had 64% with PRD versus 9% with TP53 VAF above the median ( p =0.024). Among 22 pts with TP53 alterations, 4 pts had serial Signatera testing, of which 1 exhibited PRD. The pt with PRD had low TP53 VAF and persistently rising ctDNA values. 1 pt with low TP53 VAF had a decline in ctDNA that correlated with partial response on initial restaging scan before ctDNA rise corresponded with PD on the following scan, 1 pt with low TP53 VAF had persistent undetectable values, and 1 pt with high TP53 VAF had an initial detectable value become undetectable. Conclusions: Low TP53 alteration VAF was significantly associated with PRD to EV treatment, highlighting its potential as a predictive biomarker. ctDNA monitoring may be useful to monitor treatment response on EV. These findings are exploratory and must be validated in larger cohorts.
Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).
TPS298 Background: The backbone of prostate cancer systemic treatment is androgen deprivation therapy (ADT) increasingly with the use of androgen receptor pathway inhibitors (ARPIs). Mechanisms for ARPI resistance include amplification of the androgen receptor (AR), overexpression of AR variants, aberrant AR activity, and autocrine/paracrine androgen synthesis in tumour cells. Preclinical and clinical studies have identified that bipolar androgen therapy (BAT) may restore the sensitivity of prostate cancer to ARPIs. We plan to test this hypothesis in patients with PSA progression on darolutamide for non-metastatic castrate resistant prostate cancer. Methods: WOMBAT (ANZUP 2201, NCT06594926, ACTRN12624000582550) is a single-arm phase 2 trial. The primary endpoint is to determine metastasis-free survival (MFS; time from commencing BAT to evidence of metastases or death, by conventional imaging as per PCWG3 criteria). Secondary endpoints include toxicity of BAT and darolutamide; effects on health-related quality of life; efficacy measures (PSA response rate; PSA progression-free survival); effects of BAT and darolutamide on bone turnover. Inclusion criteria include: PSA progression on darolutamide for nmCRPC; M0 on conventional imaging. Treatment consists of BAT (IM testosterone enanthate 500mg) day 1 and darolutamide 600mg bd days 29-56 (of a 56-day cycle) with ongoing ADT. The total sample size of 69 (with a first stage of enrolment of 44) is calculated to demonstrate an increase in the proportion of participants without detectable metastases at 6 months from 56.1% to 66.7% (corresponding to a median MFS improvement from 7.2 to 10.27 months, HR 0.6) with a one-sided type I error of α = 10% and power of 80%, based on benchmarks from the ARAMIS trial of darolutamide in nmCRPC. Enrolment has commenced at 8 sites around Australia. Clinical trial information: ACTRN12624000582550 .
Transferrable, wet-chemistry-derived high-k amorphous metal oxide dielectrics for two-dimensional electronic devices
Impact of homologous recombination repair alterations ( <i>HRRalt</i> ) on survival outcomes of patients (Pts) with metastatic hormone-sensitive prostate cancer (mHSPC).
205 Background: Up to 30% of pts with advanced prostate cancer have HRRalt [PMID: 32343890]. The presence of tumor HRRalt has been associated with poor prognosis in the metastatic castration-resistant setting [PMID: 38417742]. However, the impact of HRRalt in patients with mHSPC is unknown. Herein, we sought to interrogate the effect of HRRalt on the survival outcomes of pts with mHSPC. Methods: This IRB-approved retrospective study used the nationwide (US-based) de-identified Flatiron Health-Foundation Medicine prostate cancer clinico-genomic database (FH-FMI CGDB). The de-identified data originated from approximately 280 US cancer clinics (~800 sites of care). Inclusion criteria: de novo mHSPC, tissue biopsy within 90 days of diagnosis, and initiation of androgen deprivation therapy intensification (ADTi) with androgen receptor pathway inhibitor (ARPI) or taxane within 120 days of diagnosis. Survival outcomes were compared between pts with wild-type HRR ( wtHRR ) and those with HRRalt in 14 pre-specified genes per the olaparib FDA label. Time to castration-resistance (TTCR) was defined from the start of therapy for mHSPC to clinical, biochemical, or radiographic progression or death. Overall survival (OS) was defined from treatment initiation for mHSPC to death, or censored at the last follow-up. TTCR and OS indexed from metastatic diagnosis, were evaluated with Cox proportional hazards models adjusted for baseline prognostic factors. OS risk intervals were left truncated to date of comprehensive genomic profiling report to adjust for immortal time. Exploratory analyses were conducted to evaluate the association of individual HRR genes on survival outcomes in subgroups with sufficient events. Results: 637 pts were eligible and included (181 HRRalt , 28.4%), of whom 378 received an ARPI, and 259 received a taxane. The median age of the overall cohort was 68 (IQR 61 – 75). Results are summarized (Table). Conclusions: This is the largest real-world study to show significantly shorter TTCR in pts with mHSPC harboring HRRalt. No differences were observed in OS. However, CDK12m was enriched for less favorable TTCR and OS for both ARPI and taxane, highlighting an unmet need. These hypothesis-generating data may inform future clinical trial design and counseling of pts with mHSPC and HRRalt . Adjusted hazard ratio (aHR) for TTCR and OS. Genetic alteration Subgroup TTCR (aHR; 95% CI, p) OS (aHR; 95% CI, p) HRRalt vs. wtHRR ADT + ARPI 1.5; 1.1 – 2.0 1.1; 0.80 – 1.6 HRRalt vs. wtHRR ADT + Taxane 1.7; 1.2 – 2.3 1.2; 0.88 – 1.7 BRCA1/2 alt. vs. wtBRCA ADT + ARPI 1.7; 1.1 – 2.5 1.1; 0.67 – 1.8 BRCA1/2 alt. vs. wtBRCA ADT + Taxane 1.5; 0.92 – 2.3 1.1; 0.67 – 1.8 ATMm vs. wtATM ADT + ARPI 0.95; 0.50 – 1.8 0.82; 0.38 – 1.8 ATMm vs. wtATM ADT + Taxane 1.4; 0.65 – 2.9 1.3; 0.53 – 3.2 CDK12m vs. wtCDK12 ADT + ARPI 1.7; 1.1 – 2.8 1.7; 1.0 – 3.0 CDK12m vs. wtCDK12 ADT + Taxane 3.2; 2.0 – 5.3 1.7; 0.98 – 2.9
Temporal trends and socioeconomic determinants of cytoreductive nephrectomy (CN) utilization for metastatic renal cell carcinoma (mRCC) in the United States (US).
447 Background: The evolving treatment landscape in mRCC since the advent of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has rendered the role of CN unclear. We sought to quantify CN utilization in the US over the past two decades and assess factors that affect equitable access to CN. Methods: We performed an analysis of the National Inpatient Sample database, using ICD-9 and ICD-10 diagnostic and procedure codes to identify mRCC patients undergoing CN from 2006 to 2021. We calculated annual CN utilization rates, stratified by demographic and socioeconomic factors. We then performed univariable and directed acyclic graph-guided multivariable logistic regression analyses to determine the effect of demographic, socioeconomic, and clinical factors on CN utilization rates. Results: There has been a significant decrease in CN utilization in 2021 compared to 2006 (8.7% vs. 15.8%; OR 0.51, 95% CI 0.42-0.61), consistent across all demographic and socioeconomic groups. Factors associated with decreased CN utilization include Black race (OR 0.70, 95% CI 0.64-0.76), Hispanic race (OR 0.87, 95% CI 0.80-0.95), female gender (OR 0.94, 95% CI 0.90-0.98), being a Medicare (aOR 0.69, 95% CI 0.64-0.73) or Medicaid beneficiary (aOR 0.59, 95% CI 0.54-0.64), lowest income quartile (aOR 0.84, 95% CI 0.78-0.90), Southern US location (aOR 0.83, 95% CI, 0.74-0.93), and treatment in small-sized (aOR 0.57, 95% CI 0.51-0.63) or rural hospitals (aOR 0.33, 95% CI 0.27-0.40). CN utilization has significantly decreased during the ICI era compared to the TKI era (OR 0.69, 95% CI 0.64-0.75). Conclusions: CN utilization has steadily declined across the US over the past two decades, reflecting the uncertainty surrounding its role in mRCC management as new systemic therapies emerge. Access to CN is marked by significant demographic and socioeconomic disparities. Defining the evolving role of CN in the current mRCC treatment era and addressing these disparities is crucial to optimize patient outcomes. Characteristic Univariable analysis(OR [95% CI]) p -value Multivariable analysis(aOR [95% CI]) p -value Black race (ref. White) 0.70 (0.64-0.76) <0.001 - - Hispanic race (ref. White) 0.87 (0.80-0.95) 0.001 - - Female gender (ref. male) 0.94 (0.90-0.98) 0.008 - - 1 st quartile income (ref. 4 th quartile) 0.79 (0.73-0.85) <0.001 0.84 (0.78-0.90) <0.001 Medicare (ref. private insurance) 0.55 (0.53-0.58) <0.001 0.69 (0.64-0.73) <0.001 Medicaid (ref. private insurance) 0.58 (0.54-0.63) <0.001 0.59 (0.54-0.64) <0.001 Southern US (ref. Northeastern US) 0.82 (0.73-0.92) 0.001 0.83 (0.74-0.93) 0.002 Small hospital (ref. large hospital) 0.56 (0.50-0.62) <0.001 0.57 (0.51-0.63) <0.001 Rural hospital (ref. urban teaching hospital) 0.32 (0.27-0.38) <0.001 0.33 (0.27-0.40) <0.001
Image-based artificial intelligence algorithms for molecular diagnostics in prostate pathology: How far are we? A systematic review.
193 Background: Guidelines recommend molecular diagnostics for homologous and mismatch repair (MMR) defects in men with metastatic castration-resistant prostate cancer. However, in clinical practice, routine testing is hindered because it is costly, time-consuming and not available in all laboratories. Moreover, many patients need to be tested to identify the few with these genetic aberrations. To address these challenges, image-based artificial intelligence (AI) algorithms have been developed to predict molecular alterations from hematoxylin and eosin (HE) slides that are beyond the pathologist's visual detection. This review aims to assess the advancements of image-based AI algorithms in molecular diagnostics in prostate pathology and their potential in daily clinical practice. Methods: Through a search query, 3213 articles were identified and screened by two reviewers. In total, 12 articles were selected for this review and were assessed using the QUADAS-2 criteria. Results: Out of 12 articles, 5 focused exclusively on a specific set of preselected genes in prostate cancer, while the other articles examined broader ranges of genomic or transcriptomic changes, with some covering various cancer types. Training datasets consisted of up to 451 prostate cancer slides and most studies included only slides from radical prostatectomies. The majority made use of the cancer genome atlas program (TCGA). The best performance reported was 0.91 area under the curve (AUC) on internal and AUC of 0.89 on external validation. However, only 5 of the 12 studies performed external validation and none looked into the application of their algorithm in a clinical setting. Conclusions: Our review shows that in concept, AI is reasonably capable of detecting molecular changes based on HE slides of prostate pathology with reasonable predictive power. This has been shown in different specific genetic alterations, as well as in genome- or transcriptome-wide alterations. The predictive power of AI may however not be good enough to forgo molecular testing in patients predicted negative. Furthermore, these systems have only reached the developmental stage, leaving their potential performance in a clinical setting yet to be determined.
Time to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial.
173 Background: It is well-established that pts with de-novo mHSPC have poorer survival compared to those with metachronous disease. However, the impact of timing of metastatic recurrence after definitive therapy on survival has not been extensively evaluated in pts with mHSPC. Therefore, we assessed the prognostic value of TTM using the SWOG 1216 trial data which randomized pts with mHSPC to androgen deprivation therapy (ADT) with orteronel (ORT) or bicalutamide (bic) (NCT01809691). Methods: Eligibility: Only pts with metachronous mHSPC who underwent prostatectomy were included in the analysis. Metachronous disease was defined as no evidence of metastasis within 90 days of initial prostate cancer diagnosis. TTM was defined from the time of prostatectomy to the time of initial metastatic diagnosis and was analyzed as a continuous variable, then categorized. Multivariable analyses for progression-free survival (PFS) and overall survival (OS) were performed using a Cox proportional hazards model, adjusting for treatment arm, disease burden, Gleason score, performance status, log-transformed PSA, and age. Results: Of the 1279 study participants, 301 underwent prostatectomy and had metachronous mHSPC, of whom 161 were in the experimental arm and 140 in the control arm. In the overall cohort, a longer TTM was not associated with improved PFS (HR 1.0, P=0.3) and OS (HR 1.0, P=0.14). Similarly, after stratification of TTM using 1, 2, 3, and 4 year-thresholds, there was no association with PFS and OS. Results remained comparable in the subgroups of pts receiving ADT + bic and ADT + ORT separately (Table). Conclusions: The timing of metastatic disease after prostatectomy in pts with metachronous mHSPC did not appear to be related to survival and should not be used as a prognostic factor nor to predict treatment outcomes. ADT + ORT ADT Overall HR (P-value) PFS OS PFS OS PFS OS TTM Continuous 1.0 (0.8) 1.0 (0.8) 1.0 (0.3) 1.0 (0.1) 1.0 (0.3) 1.0 ( 0.1) TTM <1 vs ≥1 1.1 (0.8) 1.4 (0.5) 0.9 (0.9) 1.7 (0.2) 1.1 (0.8) 1.6 (0.1) TTM <2 vs ≥2 1.1 (0.7) 1.6 (0.3) 1.1 (0.6) 1.9 (0.1) 1.2 (0.3) 1.8 (0.04) TTM <3 vs ≥3 1.1 (0.7) 1.4 (0.4) 1.5 (0.1) 1.7 (0.1) 1.4 (0.08) 1.6 (0.09) TTM <4 vs ≥4 0.9 (0.8) 0.9 (0.9) 1.7 (0.03) 1.4 (0.4) 1.5 (0.05) 1.3 (0.4)
Circulating tumor DNA (ctDNA) monitoring in the assessment and prediction of the efficacy of PARP inhibitors (PARPi).
TPS307 Background: PARP inhibitors (PARPi) emerged as an promising treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA1/2 mutation. However, prediction of treatment response remains a challenge. Still, some patients with mutations other than BRCA1/2 responded to PARPi. Circulating tumor DNA (ctDNA) is a promising biomarker that can offer real-time insights into tumor dynamics, allowing for non-invasive monitoring of therapeutic efficacy. This study aims to assess ctDNA monitoring as a predictor of response and relapse for mCRPC patients receiving PARPi. Methods: This trial is an open-label, single-center, observational, prospective cohort study. This study intends to enroll 30 male mCRPC participants aged 18 to 75 years, who have progressed from second-line treatment at mCRPC stage and exhibit homologous recombination deficiency (HRD) or carrying DNA damage repair (DDR) gene mutations. The study involves whole blood and tumor tissue sampling for ctDNA detection, homologous recombination repair (HRR) gene testing, and whole exome sequencing. The primary outcomes include radiological progression-free survival (rPFS), objective response rate (ORR), and PSA response rate, with overall survival (OS) as a secondary outcome. The Institutional Review Board of Sun Yat-sen University Cancer Center approved this study. Recruitment is ongoing, with a target follow-up duration of 12 months and 26.7% (8/30) of the target sample size achieved. Data analysis is expected to commence in 2025 upon completion of recruitment. Clinical trial information: NCT05116579 .
<i>MTAP</i> loss in primary kidney tumors: A comprehensive genomic profiling study.
564 Background: Kidney tumors (KT) comprises approximately 4% of all new cancer cases in US per year, with about a third being de-novo metastatic. 5-Methylthioadenosine phosphorylase (MTAP) is a key enzyme in the methionine salvage pathway & has emerged as a putative biomarker for synthetic lethality-based trials testing Protein Arginine Methyltransferase 5 (PTMT5) & Metastasis-associated protein 2 (MTA2) inhibitors. We compared the genomic landscape in KT with vs without MTAP loss (del). Methods: From 541,919 consecutive cases of clinically advanced cancers, 5,467 consecutive cases of recurrent & metastatic KT underwent hybrid-capture based Comprehensive Genomic Profiling (CGP) to identify all classes of genomic alterations (GA), Microsatellite Instability (MSI) status, & tumor mutation burden (TMB). Programmed Cell Death Ligand 1 (PD-L1) expression was determined by IHC (Dako 22C3). Results were evaluated using the Fisher Exact method. Results: The overall MTAP del frequency in all KT was 10.9%. At 26.3% MTAP del frequency was highest in urothelial carcinoma (uCA) followed by not otherwise specified renal cell carcinoma (nosRCC) (13.3%), collecting duct (cdRCC) (12.5%), sarcomatoid (srcRCC) (11.7%), papillary (papRCC) (7.3%) & clear cell (ccRCC) (4.0%). Chromophobe & medullary RCC were devoid of MTAP del cases. Tendencies for patients with MTAP del KT to be slightly older & more often of male gender were noted. Across uCA & the RCC subtypes, the frequencies of driver GA were higher in MTAP del vs MTAP intact cases (Table). CDKN2A was co-deleted in 99.6% & CDKN2B in 92.8% cases of KT. For ccRCC the Von Hippel-Lindau ( VHL) GA was higher in MTAP intact than MTAP del (76.4% vs 67.0%; p=.029). Biomarkers that may correlate with immune-checkpoint inhibitor efficacy, including MSI-high status (0-4%) & median TMB level (2.5-5 mutations/Mb), as well as PD-L1 low-high expression (29-69%), did not differ significantly by MTAP del status in all KT types. Conclusions: At 11% overall, MTAP del is a relatively common GA in advanced KT including uCA & RCC cases. MTAPdel was more frequent in non-clear cell RCC, collecting duct carcinomas, & sarcomatoid histology, generating hypotheses for targeted therapy clinical trials. Limitations include retrospective nature, lack of clinical data annotation, selection & confounding biases. Further evaluation of KT, including uCA & RCC, for MTAP del-enabled PTMT5 & MTA2 inhibitor trials seem warranted. MTAPdel Top GA in MTAP del Top GA in MTAPi ntact uCA 26.3% FGFR3 34.7%, PIK3CA 20.4%, ERBB2 7.4% FGFR3 25.4%, PIK3CA 19.8%, ERBB2 13.0% nosRCC 13.3% NF2 25.6%, VHL 17.9%, PTEN 12.8% NF2 13.0%, VHL 27.6%, PTEN 5.1% ccRCC 4.0% VHL 67.0%, PBRM1 33.0%, BAP1 23.9% VHL 76.4%, PBRM1 45.9%, BAP1 14.6% papRCC 7.3% ERBB2 8.3%, MET 16.7%, NF2 5.6% ERBB2 1.7%, MET 11.5%, NF2 11.1% srcRCC 11.7% VHL 50.0%, NF2 30.8%, TP53 19.2% VHL 39.8%, NF2 18.9%, TP53 37.8% cdRCC 12.5% NF2 33.3%, SMARCB1 0%, TERT 44.4% NF2 25.4%, SMARCB1 17.5%, TERT 1.8%
Development of an miRNA signature for individual prognostic assessment in seminoma patients.
645 Background: Due to the risk of long-term toxicities in young non-metastatic seminoma patients, surveillance regimens nowadays are the standard of care. However, up to 20% of patients will relapse and undergo further treatment, requiring even greater efforts in terms of adjuvant therapy. miRNAs are known to be very stable and robust biomarkers. This study aims to establish a prognostic miRNA profile utilizing bioinformatics tools to differentiate between metastatic (met) and non-metastatic (nmet) seminomas. Methods: MiRNA was extracted from formalin-fixed paraffin-embedded sections. Using microarray analysis (Agilent Technology), two cohorts of patients with seminoma (24 patients each, 12 nmet and 12 met) were examined. The following criteria were used to preselect relevant miRNAs: absolute median log2 fold change >0.5, distance correlation >0.5, accuracy in single-miRNA classifier trained with leave-one-out cross-validation (met vs. nmet) >0.7. Validation was performed in 88 patients (47 nmet and 41 met) through qPCR using the TaqMan assay, with RNU48, miR-191-5p, and miR-361-5p serving as references. Statistical and bioinformatics analyses were performed using the Mann-Whitney U test and machine learning algorithms. Results: The bioinformatics analysis of microarrays identified 16 miRNAs exhibiting an accuracy >70% in differentiating met tumors from nmet ones. The validation of 6 miRNAs by qPCR revealed significant expression differences between met and nmet tumors for miRNAs miR-371a-5p, miR-512-3p, miR−509−3−5p, miR-517a-3p (p<0.05), dependent on the reference used. All 4 miRNAs are higher expressed in met tumors. Synchronous met tumors exhibit stronger differences in the expression of the above-mentioned miRNAs compared to metachronous met tumors, except for miR-509-3-5p. miR-371a-5p was found to be the most robust miRNA to distinguish both synchronous and metachronous met from nmet seminomas. Classifiers trained on the PCR data for different combinations of the 6 investigated miRNAs using leave-one-out cross-validation show a medium performance (average accuracy of 0.59) including one model based on 4 miRNAs with high accuracy of 0.99. Conclusions: By using machine-learning algorithms on microarray data, we have established a miRNA signature that can differentiate metastatic from non-metastatic seminomas with high reliability. Validation of 4 miRNAs by qPCR confirms the high prognostic value of miRNAs in seminoma patients. Currently, we examine the suitability of this miRNA panel in liquid biopsy.
Variants of unknown significance (VUS) in DNA repair genes in Caucasian men with muscle invasive bladder cancer (MIBC): A case of “serendipity” pushing for a BC screening program.
683 Background: In 2021 we started an enhanced PCa screening in healthy Caucasian men with germline DNA repair pathogenic variants. Over 109 enrolled men, we found two naïve patients with bladder cancer (BC), but none with PCa. This observation prompted us to investigate the prevalence of germline pathogenic variants in patients with BC and suggest genetic counselling, testing and screening for healthy relatives of subject with BC. Methods: This is a prospective ongoing study aiming to detect, by exome analysis, the prevalence of germline pathogenic (PV), likely pathogenic (LPV) variants and variant of unknown significance (VUS) in patients with BC attending the urological department from January 2024. The following DNA repair genes were considered: ATM , ATR , MRE11A , BAP1 , BARD1 , BRCA1 , NBN , BRCA2 , PALB2 , BRIP1 , CHEK2 , RAD51C , FAM175A , RAD51D , GEN1 , and XRCC1 , plus mismatch repair genes MLH1 , PMS2 , MSH2 , and MSH6 . Healthy relatives (>35 years) of patients tested positive, are being offered genetic counselling, testing and finally screening for early detection of BC. Screening consists of urine analysis, urine cytology, ultrasound abdominal assessment and cystoscopy, when indicated, every year. The study is financed/supported by Associazione Italiana per la Ricerca sul Cancro (AIRC): Protocol ICH-2812, code IG 2020-ID-25027. Results: From January to March 2024, 41 patients with BC (25 non-muscle invasive, NMIBC and 16 muscle invasive, MIBC) were tested. Overall, we found 919 variants in the 20 DNA repair genes analysed, of which 385 rare (minor allele frequency <1%). No PV and LPV were identified, while 18 VUS were found in 12 patients (29.3%; mean age 66.75 SD 11.75 vs. 69.82 SD 13.71 in negative).The reported variants affected the following genes: ATM (4); ATR (3); BARD1 (3); PMS2 (2), and BRCA2 , CHEK2 , MSH6 , NBN , PALB2 , GEN1 (1 variant each). Interestingly, all variants were found in MIBC patients or HG-NMIBC, whereas no variant was observed in low-grade NMIBC (p< 0.00001, Fisher exact test). Patients with multiple variants had a significant lower age: mean age 58.16 SD 9.02 p<0.01. Conclusions: According to Merriam-Webster dictionary “serendipity” is the phenomenon of finding valuable or agreeable things not sought for. Starting from a PCa screening in healthy men, although no clearly pathogenic variants were identified in our BC cohort, we found the presence of about 30% of VUS linked to aggressive cancers and patient low age. Those findings challenge the current (no)recommendation on genetic counselling and testing in this setting and strongly support the urgent need to raise awareness of genetic risk for BC and to design effective public health promotion policies.
Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma.
661 Background: Most patients following radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) face a poor prognosis. Combination of chemotherapy and immunotherapy in neoadjuvant setting have demonstrated survival improvement in several tumors. Additional systemic therapy in a neoadjuvant setting may prolong survival for UTUC patients, especially those after RNU who are ineligible to receive nephrotoxic chemotherapy. Methods: Phase 2 clinical trial (NCT04617756) was conducted in 10 French centers. Eligible patients had non metastatic, high-grade disease on ureteroscopic tumor biopsy or on urine cytology and infiltrative aspect of renal pelvis/ureteral wall on CT imaging. Subjects received a combination of: Durvalumab/Gemcitabine/Cisplatin (cohort 1) or Carboplatin (cohort 2) every 3 weeks for a total of 4 cycles based on glomerular filtration rate, prior to RNU. The primary objective was to assess the pathological complete response (ypT0) rate (pCR) of each combination. Results: A total of 50 patients were enrolledbetween 2021 and 2023 (31 in cohort 1 and 19 in cohort 2). Median age was 66 years old (range 38-79), 58% were males. 90% of patients (44) received 4 cycles of treatment, 3 patients 3 cycles and 2 patients received 2 cycles. Five patients switched for carboplatin during chemotherapy. We observed in cohort 1 : 20/31 (65%) patients with non infiltrative residual tumor; In cohort 2 : 9/19 (42%) patients (table). Secondary endpoint was safety, no immunotherapy-mediated AE was observed, 2 patients had Grade 3 neutropenia, 1 grade 4, 1 patient had grade 3 thrombopenia and 1 grade 3 anemia. Conclusions: Combination of durvalumab with platin-based chemotherapy, especially cisplatin, showed promising activity in UTUC, with the occurrence of complete responses and a high rate of non-infiltrative residual tumor. Safety profile was secure without increasing surgical risk. A randomized Phase 3 controlled study comparing neoadjuvant chemotherapy with chemotherapy combined with immunotherapy in patients with high-risk localized UTUC (iNDUCT-3) will open soon to validate these encouraging results. Clinical trial information: NCT04617756 . Pathological response rate. ypT0 ypTIS /ypTa ypT1 ypT2 ypT3 ypT4 Missing data Withdrawal surgery Total Cis-Gem Durva 4 (13%) 5 (16%) 11 (36%) 1 (3%) 6 (19%) 1 (3%) 1 2 31 Carbo-Gem Durva 1 (5%) 6 (32%) 1 (5%) 3 (16%) 5 (26%) 1 (5%) 1 1 19
T suppression and recovery with AAP after early discontinuation of LHRH-A in high-risk localized (HRL), lymph node-positive (N+), or oligometastatic (OM) prostate cancer (PC).
55 Background: Intensified androgen deprivation therapy (iADT) with the addition of abiraterone acetate + prednisone (AAP) to a luteinizing hormone releasing hormone agonist or antagonist (LHRH-A) is commonly used in conjunction with radiation therapy for HRL, N+ or OM hormone-sensitive PC. However, prolonged LHRH-A has been associated with delayed or incomplete testosterone (T) recovery after discontinuation (dc). As AAP monotherapy leads to castrate T, we investigated T kinetics with early discontinuation of LHRH-A when given in combination with AAP. Methods: The Dana-Farber/Harvard Cancer Center (DF/HCC) Oncology Data Retrieval System (OncDRS) was queried to identify patients (pts) planned to receive 18-24 mo of AAP for HRL, N+ or OM PC. Pts who previously received AAP for > 12 mo, with baseline T <150 ng/dl, received AAP for castration-resistant PC, received AAP >30 mo, or LHRH-A dc > 3 mo after AAP were excluded. T values at AAP end of treatment (EOT) and at each clinical follow up visit were tabulated to assess time to T recovery (TTR) to ≥150 ng/dl in pts with LHRH-A dc ≤3 mo, 3-12 mo and ≥12 mo prior to AAP EOT. Gray’s competing risk regression model was applied to assess the relationship between TTR and time between LHRH-A dc and AAP EOT. Results: The OncDRS query returned 350 pts, 105 meeting eligibility criteria with available T follow up after AAP EOT. 99 of 105 pts had available T at EOT, 99/99 (100%) with T < 20 ng/dl across the three groups. TTR was statistically significantly shorter for pts with LHRH-A dc ≥12 months prior to AAP EOT (median 3.2 mo [95% CI 1.8, 4.1]) compared to ≤3 mo prior to LHRH-A dc (median 20.0 mo [9.0, 27.6]) with all T recovery events within 6 months of EOT in the former group (Table). Conclusions: In this real-world cohort, early discontinuation of LHRH-A when given in combination with AAP led to ongoing T suppression while on AAP and shorter TTR after AAP EOT. This strategy warrants consideration when iADT is indicated but the patient seeks rapid and reliable T recovery after completion of treatment for the actual duration of T suppression desired. DF/HCC protocol # 23-322. TTR outcome summary. Timing of discontinuation of LHRH-A ≥ 12 months (N=13) 3 – 12 months (N=36) ≤ 3 months (N=56) No. T recovery events 10 26 26 No. competing events* 0 1 6 6-month cumulative TTR rate (95% CI) 82% (38%, 96%) 39% (23%, 55%) 15% (6.8%, 26%) 12-month cumulative TTR rate (95% CI) 82% (38%, 96%) 64% (46%, 78%) 39% (25%, 52%) Median (95%), month 3.2 (1.8, 4.1) 7.5 (3.7, 15.5) 20.0 (9.0, 27.6) Hazard ratio (95% CI) ref 0.40 (0.16, 1.02) 0.20 (0.08, 0.49) p-value ref 0.06 0.01 *New treatment without T recovery.
Bacillus Calmette-Guérin (BCG) treatment patterns and real-world outcomes in high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): A systematic literature review (SLR).
730 Background: Transurethral resection followed by induction and maintenance intravesical BCG is currently standard of care for patients with HR NMIBC. HR is generally defined as stage T1, high grade (HG), carcinoma in situ, tumors >3 cm, variant histology, BCG failure in HG tumor, or lymphovascular invasion. Considering the variability in HR definitions and BCG maintenance schedules, we analyzed the evidence on maintenance utilization and outcomes in patients with HR NMIBC. Methods: We conducted an SLR of English-language real-world evidence (RWE) studies published 01/01/2011–06/12/2024 reporting efficacy or safety outcomes with BCG in patients with HR NMIBC using MEDLINE, Embase, and Cochrane supplemented by manual searches of relevant conference proceedings 2021–2024. Studies reporting treatment patterns or progression-/recurrence-related outcomes were analyzed. Results: Among 244 RWE studies identified, 86 reported data on HR populations, which was defined by commonly accepted definitions such as T1 high grade (HG) or any HG, with 37.2% using AUA/EAU guidelines. Across studies reporting BCG maintenance patterns in the HR population, 40.7% of patients (6,795/16,712; 16 studies) received some form of maintenance. Details on maintenance duration were reported in 11 studies; among them, 27.9% of patients (1,154/4,142) completed ≥1 year of maintenance. Details on adequate BCG treatment were reported in 8 studies, defined as receipt of ≥5/6 induction instillations and ≥2/3 maintenance instillations. Across these eight studies, 59.5% of patients (10,122/17,007) did not receive adequate BCG treatment. While comparisons across studies should be interpreted with caution due to heterogeneity in study populations. Median 2-year recurrence-free survival (RFS), 5-year RFS, and 2-year progression-free survival (PFS) across studies was numerically longer with maintenance versus induction alone (table). However, median 5-year PFS across studies appeared similar with or without maintenance. Conclusions: Less than 50% of HR patients who started BCG treatment received some form of maintenance; however, studies were highly heterogenous in reporting patterns of BCG treatment and definitions of HR NMIBC. Although maintenance duration was underreported, ~30% of patients completed ≥1 year of maintenance. In patients with HR NMIBC, RWE suggests improved outcomes with maintenance versus induction alone. More studies are needed to confirm the benefit of different maintenance schedules and durations. Real-world efficacy outcomes: HR NMIBC population. Induction, median (range) [n studies], % Induction + maintenance, median (range) [n studies], % 2-year PFS 85.7 (81–95) [3] 92.0 (89–98) [8] 2-year RFS 66.7 (53–81) [2] 77.1 (62–85) [7] 5-year PFS 82.6 (72–89) [4] 84.0 (53–98) [13] 5-year RFS 53.0 (31–75) [6] 64.7 (27–78) [10]
Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry.
736 Background: The treatment of advanced urothelial carcinoma (UC) has dramatically changed with the introduction of antibody-drug conjugates and immunotherapy. Since the report of the EV-302 trial data in October 2023, enfortumab vedotin (EV) in combination with pembrolizumab (P) is the preferred standard of care in 1 st line therapy. Methods: Clinical data were derived from 17 clinics participating in the Austrian EV registry. Patients receiving 1 st line EV + P for advanced UC from 09/2023 to 09/2024 were included. The main objectives of the registry were to evaluate patient characteristics, including comorbidities, treatment duration, efficacy and safety in a real-world setting. Results: In total 103 patients were included, 24 females and 79 males with a median age of 71 years (range 32 - 92). The majority of patients (89.3%) had an eastern cooperative oncology group performance status (ECOG PS) of 0 to 1, 6.7 % patients had an ECOG PS of 2 and 3.8% had an ECOG PS of 3. Liver metastasis was present in 19.4% of patients. At the time of data cut-off, 81.6% of patients were alive. Therapy with either EV or P was ongoing in 67.0% of patients. First response evaluation was performed in 88 patients, of these the objective response rate (ORR) was 65.9% with 12.5% complete remissions. After a median follow up of 4.0 months, the median overall survival (OS) and progression free survival (PFS) was not reached. Adverse events occurred in 69.9% of patients, with ≥ grade 3 toxicities in 30.1% of patients. Therapy with either EV or P was discontinued due to toxicity in 20.4% of patients. Patients with a high (≥5) Charlson comorbidity index (CCI) had significantly worse outcomes in terms of ORR (p = 0.02), PFS (p = 0.02) and OS (p = 0.04) as compared to patients with a lower CCI (0-4). There was also a trend for more severe adverse events in patients with a high CCI (p = 0.07), however, the overall adverse event rate, dose reductions and treatment discontinuations were similar in both groups. Renal function, body mass index and known diabetes mellitus had no influence on efficacy or tolerability in our analysis. In patients with ECOG PS 2 the ORR was 71.4% which is numerically similar to patients with ECOG PS 0-1. Conclusions: These first Austrian real-world data evaluate the efficacy and tolerability of EV plus P in routine clinical practice. Our data confirm the ORR to the pivotal EV-302 phase III trial, however patients with significant comorbidities as reflected by a higher score in the CCI had significantly worse outcomes. Updated data with longer follow up will be presented at the meeting.
Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic renal cell carcinoma with chromophobe histology.
488 Background: Chromophobe (chRCC) renal cell carcinoma are rare cancers and obtain a worse prognosis. We evaluated real-world treatment outcomes of 1 st line treatment in these cohort in Germany. Methods: We retrospectively analyzed patients with metastatic chRCC treated at 17 German tertiary cancer centres being treated from 2008-2023. Adverse events (AE) were reported according to CTCAE 5.0, objective response rate (ORR) according to local standard of radiological and clinical judgement. Progression free survival (PFS) and overall survival (OS) were calculated from start of treatment to progression or death, respectively and determined by KM plots. Results: We included 39 patients with a median age of 59 (IQR 55-71) years. ECOG PS was 0/1/≥2 in 70/17/12%. IMDC risk was favorable/intermediate/poor in 13/61/26%. 87% received prior nephrectomy. Lymphatic (58%), pulmonary (37%) bone (34%) and metastases were the most common metastatic sites. 52% patients received first-line IO-combinations (IO-IO: 43%, TKI-IO: 57%) and 48% patients TKI-monotherapy, predominantly sunitinib. Subsequent therapy was mostly Cabozantinib (after IO-IO), Lenvatinib/Everolimus (after IO-TKI) or Nivolumab (after TKI mono). AE of all grades occurred in 59% and 71% during IO-based therapy or TKI monotherapy, and CTCAE grade ≥3 in 29% or 25%, respectively. ORR and survival outcomes with median follow-up of 14 months (IQR 7-28) are described in the table. Conclusions: IO-combinations are frequently applied in chRCC. Our data suggests that first-line IO-/TKI-based combinations yields higher ORR compared to IO-/IO-based combinations and single agent TKI, but did not translate into an improved PFS or OS. The retrospective nature and small sample size are major limitations of our analysis. However, the rarity of metastatic chRCC contributes to inconsistent findings not only in our dataset but also across previously published studies, making it difficult to establish clear treatment guidelines. Further research is essential to refine treatment strategies for patients with metastatic chRCC. ORR and survival outcomes of study population. Parameter All therapies (n=31) IO/IO (n=8) IO/TKI (n=10) TKI (n=13) ORR (CR+PR) 19% 12,5% 30% 15% SD 16% 12,5% 40% 0% PD 65% 75% 30% 85% ORR vs. SD vs. PD - p=0.05 Parameter All therapies IO/IO IO/TKI TKI mPFS, months, 95% CI 3 (0,0-10,2) 3 (2,4-3,6) 8 (0,0-19,2) 4 (0,0-10,2) - P=0.077 mOS; months, 95% CI 24 (22,7-25,3) 12 (2,3-21,7) NR (NR-NR) 24 (22,5-25,5) - p=0.183
Targeting more than tumors: The impact of enfortumab vedotin and pembrolizumab (EV/P) on skeletal muscle loss and sarcopenia in metastatic urothelial carcinoma (mUC).
689 Background: Sarcopenia and skeletal muscle loss are associated with poor prognosis and limited survival in metastatic cancer patients. This study aims to assess the impact of systemic treatment with enfortumab vedotin and pembrolizumab (EV/P) on skeletal muscle index (L3SMI) in patients with metastatic urothelial carcinoma (mUC). Methods: We conducted a retrospective analysis of mUC patients treated with EV/P at a single German tertiary care center. L3SMI was measured at baseline (before treatment) and at the first radiographic staging, approximately three months post-treatment on routinely obtained CT (computed tomography) or PET CT (positron emission tomography) imaging. L3 muscle area was measured using OsiriX software and normalized by height squared to calculate L3SMI. Sarcopenia was defined using L3SMI cutoffs based on body mass index (BMI): for men with BMI <25 kg/m², L3SMI <43 cm²/m²; for men with BMI ≥25 kg/m², L3SMI <53 cm²/m²; and for women, regardless of BMI, L3SMI <41 cm²/m². Results: Between November 2023 and October 2024, 24 patients with metastatic urothelial carcinoma (mUC) who had available imaging were included in the analysis. The median time between baseline and first follow-up imaging was 84 days. At baseline, 46% of patients met the criteria for sarcopenia, and by the first follow-up, 33% had experienced significant L3SMI loss (>4%), leading to 50% of patients being classified as sarcopenic. Despite this, significant L3SMI loss was not associated with poorer radiographic staging outcomes. Of the patients, 62.5% achieved a partial response (PR), 25% had stable disease (SD), and 12.5% showed progressive disease (PD). Conversely, 16% of patients showed a significant gain in L3SMI during the same period. A moderate, non-significant correlation was found between sarcopenia at first follow-up and treatment-related adverse events (r=0.339, p=0.11 ). In contrast, a significant correlation was observed between the onset of therapy-induced peripheral neuropathy and sarcopenia (r=0.418, p=0.042 ). Conclusions: This study emphasizes the high prevalence of sarcopenia in real-world mUC patients undergoing EV/P therapy, along with notable muscle loss within the first few months of treatment. Interestingly, this early decline in L3SMI did not correlate with poorer radiographic outcomes. Given that EV/P is a continuous therapy with the inevitable development of cumulative toxicities, monitoring muscle loss may help to implement strategies to avoid them. Our findings suggest a potential causal relationship between EV/P therapy and L3SMI loss, warranting further investigation. Larger studies with extended follow-up are needed to gain deeper insight into the long-term impact of sarcopenia in patients receiving EV/P treatment.